期刊
PHARMACEUTICS
卷 15, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics15010202
关键词
pantothenate kinase-2 associated neurodegeneration; leriglitazone; hiPS-derived astrocytes; nuerodegeneration with brain iron accumulation
This study tested the effectiveness of the brain-penetrant peroxisome proliferator-activated receptor gamma agonist leriglitazone in ameliorating mitochondrial defects in a cellular model of Pantothenate kinase-2 associated Neurodegeneration (PKAN). The results showed that leriglitazone improved the viability and respiratory activity of PKAN cells, while reducing iron accumulation, suggesting it could be a beneficial therapeutic approach for PKAN treatment.
The novel brain-penetrant peroxisome proliferator-activated receptor gamma agonist leriglitazone, previously validated for other rare neurodegenerative diseases, is a small molecule that acts as a regulator of mitochondrial function and exerts neuroprotective, anti-oxidative and anti-inflammatory effects. Herein, we tested whether leriglitazone can be effective in ameliorating the mitochondrial defects that characterize an hiPS-derived model of Pantothenate kinase-2 associated Neurodegeneration (PKAN). PKAN is caused by a genetic alteration in the mitochondrial enzyme pantothenate kinase-2, whose function is to catalyze the first reaction of the CoA biosynthetic pathway, and for which no effective cure is available. The PKAN hiPS-derived astrocytes are characterized by mitochondrial dysfunction, cytosolic iron deposition, oxidative stress and neurotoxicity. We monitored the effect of leriglitazone in comparison with CoA on hiPS-derived astrocytes from three healthy subjects and three PKAN patients. The treatment with leriglitazone did not affect the differentiation of the neuronal precursor cells into astrocytes, and it improved the viability of PKAN cells and their respiratory activity, while diminishing the iron accumulation similarly or even better than CoA. The data suggest that leriglitazone is well tolerated in this cellular model and could be considered a beneficial therapeutic approach in the treatment of PKAN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据